2.2 Salt Forms and Active Ingredient Verification

Salt Forms and Active Ingredient Verification

Core Verification Rule: A difference in drug salt, ester, or complex constitutes a Pharmaceutical Alternative, NOT a pharmaceutical equivalent. Swapping salt forms without a new prescription or direct prescriber authorization is illegal under state pharmacy practice acts and puts patients at severe risk of therapeutic failure or acute toxicity.

In pharmaceutical chemistry, active drug molecules are frequently combined with inorganic or organic counter-ions to form salts. Synthesizing a drug as a specific salt form modifies its chemical stability, aqueous solubility, dissolution rate in gastrointestinal fluids, palatability, and pharmacokinetic absorption profile.

For pharmacy technicians performing final product verification, distinguishing between different salt forms of the same parent drug molecule is one of the most critical safety checkpoints.

---

1. Why Salt Forms Are Not Automatically Interchangeable

When a prescriber orders a medication with a specific salt form, that choice directly dictates:

1. Rate of Dissolution and Absorption ($T_{max}$): Certain salts dissolve rapidly in gastric acid (providing immediate pain relief), while other salts are insoluble in stomach acid and require alkaline intestinal pH for dissolution.
2. Duration of Therapeutic Action ($t_{1/2}$ and Release Curves): Heavy or complex salts often slow down absorption, enabling once-daily sustained release, whereas simple hydrochloride salts may produce sharp peak serum concentrations requiring multiple daily doses.
3. Stoichiometric Active Moiety Weight: A 500 mg tablet of Salt Form A does not contain the same amount of active base molecule as a 500 mg tablet of Salt Form B because the counter-ions have different molecular weights.
4. FDA Approved Indications: Distinct salts of the identical chemical base are often approved for entirely different medical conditions.

Pharmaceutical Alternative ≠ Pharmaceutical Equivalent
Generic Substitution Allowed ONLY for Pharmaceutical Equivalents

---

2. High-Risk Clinical Salt Pairs in Verification

1. Metoprolol Succinate vs. Metoprolol Tartrate

This is the single most frequent and clinically dangerous salt form error encountered in ambulatory and institutional pharmacy practice.

[!CAUTION] Clinical Impact of a Metoprolol Salt Swap:

• If Tartrate is erroneously dispensed for a Succinate once-daily order: The patient receives rapid beta-blockade for 6–8 hours followed by 16 hours with zero beta-blocker coverage, triggering rebound hypertension, tachycardia, and potential ischemic cardiac events.
• If Succinate is erroneously dispensed for a Tartrate BID/TID order: The extended-release formulation accumulates in serum over consecutive doses, causing profound bradycardia, complete heart block, acute hypotensive shock, and cardiogenic collapse.

---

2. Hydroxyzine Hydrochloride vs. Hydroxyzine Pamoate

Hydroxyzine is a first-generation piperazine antihistamine available in two distinct salt forms with different pharmacokinetic properties and clinical uses.

During verification, technicians must verify the exact salt against the prescription: a prescription for Atarax must be filled with hydroxyzine hydrochloride tablets, never hydroxyzine pamoate capsules, and vice versa.

---

3. Diclofenac Sodium vs. Diclofenac Potassium

Diclofenac is a potent non-steroidal anti-inflammatory drug (NSAID) whose salt counter-ion completely changes its dissolution site and clinical utility.

---

4. Erythromycin Salt and Ester Discrepancies

Erythromycin base is rapidly inactivated by gastric acid. To overcome this instability, pharmaceutical manufacturers synthesized multiple ester and salt derivatives. However, because each derivative possesses a different molecular weight, they are not stoichiometrically equivalent.

[!WARNING] The 400 mg vs. 250 mg Erythromycin Stoichiometric Trap: Because erythromycin ethylsuccinate (EES) has a heavier ester group, 400 mg of EES is required to deliver 250 mg of active erythromycin base. If a technician mistakenly dispenses 400 mg of Erythromycin Stearate or Base instead of 400 mg of EES, the patient receives a 60% active drug overdose.

---

5. Diltiazem Hydrochloride Formulation Matrix

Diltiazem hydrochloride is available in numerous multi-source formulations that are NOT universally bioequivalent to one another. Because several diltiazem extended-release brands are each their own Reference Listed Drug, the Orange Book assigns them different three-character subcodes, and a generic is interchangeable only with the brand whose subcode it shares:

A generic diltiazem ER capsule rated AB3 (equivalent to Cardizem CD) CANNOT be dispensed against a prescription written for Tiazac (AB4) without a pharmacist intervening and obtaining prescriber authorization. Verify the subcode in the current Orange Book at the time of dispensing — these ratings are revised as products are added, reformulated, or discontinued.

---

6. Amphetamine Mixed Salts vs. Lisdexamfetamine

In central nervous system stimulant therapy, verifying the exact molecular composition is critical for both therapeutic efficacy and DEA Schedule II controlled substance compliance:

• Adderall (IR) / Adderall XR: Composed of a 3:1 ratio of dextroamphetamine to levoamphetamine across four specific salts: dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate. It provides immediate or dual-pulse release of active amphetamine.
• Vyvanse (Lisdexamfetamine dimesylate): A synthetic prodrug consisting of L-lysine covalently bonded to dextroamphetamine. Lisdexamfetamine is pharmacologically inactive until the enzymatic cleavage of the lysine amino acid occurs via red blood cells in the bloodstream, conferring abuse-deterrent, smooth 12-hour kinetics.
• Verification Checkpoint: Lisdexamfetamine is a single prodrug molecule, not a mixed salt. These medications are completely non-interchangeable.

---

3. Systematic Verification Protocol for Salt Forms

When performing product verification on any prescription involving multi-salt drugs, follow this 4-step protocol:

1. Step 1: Check the Specific Salt Suffix on the Prescription Order: Confirm whether the prescriber specified succinate vs. tartrate, hydrochloride vs. pamoate, sodium vs. potassium, or monohydrate vs. anhydrous.
2. Step 2: Confirm Matching Stock Bottle Salt: Inspect the manufacturer bottle label to ensure the chemical salt exactly matches the order. Do not rely solely on the stem name (e.g., seeing 'Metoprolol' is insufficient—verify 'Metoprolol Succinate Extended-Release').
3. Step 3: Correlate Dosing Frequency with Formulation Kinetics: Cross-check the prescribed directions against the salt's pharmacokinetic profile. If metoprolol succinate is ordered 'take 1 tablet twice daily' or metoprolol tartrate is ordered 'take 1 tablet once daily', flag this immediately for pharmacist clinical review.
4. Step 4: Check Dosage Form Integrity: Ensure extended-release salt matrices (e.g., Toprol-XL, Cardizem CD, Voltaren-XR) are not flagged for crushing or administration via fine-bore enteral feeding tubes.